LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 327 of 535
Next
>>
>
8151 to 8175 of 13356 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	SNS-032	3.33	uM	LJP6	3	H14	72	hr	1097	716	3696	0.1937	-0.2162
BT-20	SNS-032	10	uM	LJP6	1	H13	72	hr	1097	701	3610	0.1942	-0.2295
BT-20	SNS-032	10	uM	LJP6	2	H13	72	hr	1097	847	3713	0.2281	-0.1369
BT-20	SNS-032	10	uM	LJP6	3	H13	72	hr	1097	777	3696	0.2102	-0.1788
BT-20	Afatinib	0.04	uM	LJP6	1	G24	72	hr	1097	2735	3610	0.7575	0.7015
BT-20	Afatinib	0.04	uM	LJP6	2	G24	72	hr	1097	2950	3713	0.7944	0.7546
BT-20	Afatinib	0.04	uM	LJP6	3	G24	72	hr	1097	2938	3696	0.7948	0.7543
BT-20	Afatinib	0.12	uM	LJP6	1	G23	72	hr	1097	3096	3610	0.8575	0.8288
BT-20	Afatinib	0.12	uM	LJP6	2	G23	72	hr	1097	2895	3713	0.7795	0.7360
BT-20	Afatinib	0.12	uM	LJP6	3	G23	72	hr	1097	3106	3696	0.8403	0.8109
BT-20	Afatinib	0.37	uM	LJP6	1	G22	72	hr	1097	3214	3610	0.8902	0.8691
BT-20	Afatinib	0.37	uM	LJP6	2	G22	72	hr	1097	3245	3713	0.8738	0.8523
BT-20	Afatinib	0.37	uM	LJP6	3	G22	72	hr	1097	2784	3696	0.7532	0.7013
BT-20	Afatinib	1.11	uM	LJP6	1	G21	72	hr	1097	3040	3610	0.8420	0.8095
BT-20	Afatinib	1.11	uM	LJP6	2	G21	72	hr	1097	3199	3713	0.8614	0.8374
BT-20	Afatinib	1.11	uM	LJP6	3	G21	72	hr	1097	3219	3696	0.8708	0.8482
BT-20	Afatinib	3.33	uM	LJP6	1	G20	72	hr	1097	3204	3610	0.8874	0.8657
BT-20	Afatinib	3.33	uM	LJP6	2	G20	72	hr	1097	3264	3713	0.8789	0.8585
BT-20	Afatinib	3.33	uM	LJP6	3	G20	72	hr	1097	3292	3696	0.8906	0.8720
BT-20	Afatinib	10	uM	LJP6	1	G19	72	hr	1097	885	3610	0.2451	-0.1176
BT-20	Afatinib	10	uM	LJP6	2	G19	72	hr	1097	737	3713	0.1985	-0.2025
BT-20	Afatinib	10	uM	LJP6	3	G19	72	hr	1097	827	3696	0.2237	-0.1490
BT-20	GSK1904529A	0.04	uM	LJP6	1	H24	72	hr	1097	3142	3610	0.8702	0.8446
BT-20	GSK1904529A	0.04	uM	LJP6	2	H24	72	hr	1097	2961	3713	0.7973	0.7584
BT-20	GSK1904529A	0.04	uM	LJP6	3	H24	72	hr	1097	3238	3696	0.8760	0.8544

|<
<<
Previous
Page 327 of 535
Next
>>
>
8151 to 8175 of 13356 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)